P21/waf1 protein expression in nasopharyngeal carcinoma. Comparative study with PCNA, p53 and MDM-2 protein expression. 1997

C Kouvidou, and K Stefanaki, and Y Dai, and M Tzardi, and K Koutsoubi, and K Darivianaki, and E Karidi, and D Rontogianni, and E Zois, and S Kakolyris, and V Georgoulias, and G Delides, and P Kanavaros
Department of Pathology of University Hospital of Heraklion, Greece.

We investigated the immunohistochemical expression of p21/waf1 protein in 59 cases of nasopharyngeal carcinomas (NPC) and compared p21 expression with PCNA, p53 and mdm2 protein expression. We found p21, PCNA, p53 and mdm2 in 59/59, 59/59, 18/59 and 12/59 nasopharyngeal carcinomas, respectively. We observed a tendency to a relationship between high expression of PCNA (> 25% positivity in tumour cells) and low expression of p21 protein. Parallel p53/p21 protein expression was found in 18 cases. Twelve were also mdm2 positive. This pattern may represent NPC with wild type (wt) p53 since mdm2 and p21 proteins are inducible by wt p53 gene. In these cases p53 protein expression may be due to stabilisation to mdm2 protein. This could be important in the pathogenesis of these cases since mdm2 may deregulate the p53-dependent growth suppressive pathway. Discordant p53-/p21+ protein expression was found in 41 cases. All were also mdm2 negative. This pattern suggests immunohistochemically undetectable wt p53 gene which is able to induce p21 protein expression.

UI MeSH Term Description Entries
D007150 Immunohistochemistry Histochemical localization of immunoreactive substances using labeled antibodies as reagents. Immunocytochemistry,Immunogold Techniques,Immunogold-Silver Techniques,Immunohistocytochemistry,Immunolabeling Techniques,Immunogold Technics,Immunogold-Silver Technics,Immunolabeling Technics,Immunogold Silver Technics,Immunogold Silver Techniques,Immunogold Technic,Immunogold Technique,Immunogold-Silver Technic,Immunogold-Silver Technique,Immunolabeling Technic,Immunolabeling Technique,Technic, Immunogold,Technic, Immunogold-Silver,Technic, Immunolabeling,Technics, Immunogold,Technics, Immunogold-Silver,Technics, Immunolabeling,Technique, Immunogold,Technique, Immunogold-Silver,Technique, Immunolabeling,Techniques, Immunogold,Techniques, Immunogold-Silver,Techniques, Immunolabeling
D009303 Nasopharyngeal Neoplasms Tumors or cancer of the NASOPHARYNX. Cancer of Nasopharynx,Nasopharyngeal Cancer,Cancer of the Nasopharynx,Nasopharynx Cancer,Nasopharynx Neoplasms,Neoplasms, Nasopharyngeal,Cancer, Nasopharyngeal,Cancer, Nasopharynx,Cancers, Nasopharyngeal,Cancers, Nasopharynx,Nasopharyngeal Cancers,Nasopharyngeal Neoplasm,Nasopharynx Cancers,Nasopharynx Neoplasm,Neoplasm, Nasopharyngeal,Neoplasm, Nasopharynx,Neoplasms, Nasopharynx
D009363 Neoplasm Proteins Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm. Proteins, Neoplasm
D009687 Nuclear Proteins Proteins found in the nucleus of a cell. Do not confuse with NUCLEOPROTEINS which are proteins conjugated with nucleic acids, that are not necessarily present in the nucleus. Nucleolar Protein,Nucleolar Proteins,Nuclear Protein,Protein, Nuclear,Protein, Nucleolar,Proteins, Nuclear,Proteins, Nucleolar
D011518 Proto-Oncogene Proteins Products of proto-oncogenes. Normally they do not have oncogenic or transforming properties, but are involved in the regulation or differentiation of cell growth. They often have protein kinase activity. Cellular Proto-Oncogene Proteins,c-onc Proteins,Proto Oncogene Proteins, Cellular,Proto-Oncogene Products, Cellular,Cellular Proto Oncogene Proteins,Cellular Proto-Oncogene Products,Proto Oncogene Products, Cellular,Proto Oncogene Proteins,Proto-Oncogene Proteins, Cellular,c onc Proteins
D002277 Carcinoma A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm and not a synonym for "cancer." Carcinoma, Anaplastic,Carcinoma, Spindle-Cell,Carcinoma, Undifferentiated,Carcinomatosis,Epithelial Neoplasms, Malignant,Epithelioma,Epithelial Tumors, Malignant,Malignant Epithelial Neoplasms,Neoplasms, Malignant Epithelial,Anaplastic Carcinoma,Anaplastic Carcinomas,Carcinoma, Spindle Cell,Carcinomas,Carcinomatoses,Epithelial Neoplasm, Malignant,Epithelial Tumor, Malignant,Epitheliomas,Malignant Epithelial Neoplasm,Malignant Epithelial Tumor,Malignant Epithelial Tumors,Neoplasm, Malignant Epithelial,Spindle-Cell Carcinoma,Spindle-Cell Carcinomas,Tumor, Malignant Epithelial,Undifferentiated Carcinoma,Undifferentiated Carcinomas
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D016159 Tumor Suppressor Protein p53 Nuclear phosphoprotein encoded by the p53 gene (GENES, P53) whose normal function is to control CELL PROLIFERATION and APOPTOSIS. A mutant or absent p53 protein has been found in LEUKEMIA; OSTEOSARCOMA; LUNG CANCER; and COLORECTAL CANCER. p53 Tumor Suppressor Protein,Cellular Tumor Antigen p53,Oncoprotein p53,TP53 Protein,TRP53 Protein,p53 Antigen,pp53 Phosphoprotein,Phosphoprotein, pp53
D016213 Cyclins A large family of regulatory proteins that function as accessory subunits to a variety of CYCLIN-DEPENDENT KINASES. They generally function as ENZYME ACTIVATORS that drive the CELL CYCLE through transitions between phases. A subset of cyclins may also function as transcriptional regulators. Cyclin
D050759 Cyclin-Dependent Kinase Inhibitor p21 A cyclin-dependent kinase inhibitor that mediates TUMOR SUPPRESSOR PROTEIN P53-dependent CELL CYCLE arrest. p21 interacts with a range of CYCLIN-DEPENDENT KINASES and associates with PROLIFERATING CELL NUCLEAR ANTIGEN and CASPASE 3. CDK2-Associated Protein 20 kDa,CDKN1 Protein,CDKN1A Protein,Cdk-Interacting Protein 1,Cdk2 Inhibitor Protein,Cell Cycle Regulator p21,Cyclin Kinase Inhibitor p21,Cyclin-Dependent Kinase Inhibitor 1A Protein,Senescent Cell-Derived Inhibitor Protein 1,p21 Cell Cycle Regulator,p21 Cyclin Kinase Inhibitor,CDK2 Associated Protein 20 kDa,Cdk Interacting Protein 1,Cyclin Dependent Kinase Inhibitor 1A Protein,Cyclin Dependent Kinase Inhibitor p21,Senescent Cell Derived Inhibitor Protein 1

Related Publications

C Kouvidou, and K Stefanaki, and Y Dai, and M Tzardi, and K Koutsoubi, and K Darivianaki, and E Karidi, and D Rontogianni, and E Zois, and S Kakolyris, and V Georgoulias, and G Delides, and P Kanavaros
December 1995, Clinical molecular pathology,
C Kouvidou, and K Stefanaki, and Y Dai, and M Tzardi, and K Koutsoubi, and K Darivianaki, and E Karidi, and D Rontogianni, and E Zois, and S Kakolyris, and V Georgoulias, and G Delides, and P Kanavaros
August 1998, International journal of cancer,
C Kouvidou, and K Stefanaki, and Y Dai, and M Tzardi, and K Koutsoubi, and K Darivianaki, and E Karidi, and D Rontogianni, and E Zois, and S Kakolyris, and V Georgoulias, and G Delides, and P Kanavaros
January 2004, Ai zheng = Aizheng = Chinese journal of cancer,
C Kouvidou, and K Stefanaki, and Y Dai, and M Tzardi, and K Koutsoubi, and K Darivianaki, and E Karidi, and D Rontogianni, and E Zois, and S Kakolyris, and V Georgoulias, and G Delides, and P Kanavaros
October 1997, International journal of cancer,
C Kouvidou, and K Stefanaki, and Y Dai, and M Tzardi, and K Koutsoubi, and K Darivianaki, and E Karidi, and D Rontogianni, and E Zois, and S Kakolyris, and V Georgoulias, and G Delides, and P Kanavaros
April 2004, World journal of gastroenterology,
C Kouvidou, and K Stefanaki, and Y Dai, and M Tzardi, and K Koutsoubi, and K Darivianaki, and E Karidi, and D Rontogianni, and E Zois, and S Kakolyris, and V Georgoulias, and G Delides, and P Kanavaros
January 2002, Oncology reports,
C Kouvidou, and K Stefanaki, and Y Dai, and M Tzardi, and K Koutsoubi, and K Darivianaki, and E Karidi, and D Rontogianni, and E Zois, and S Kakolyris, and V Georgoulias, and G Delides, and P Kanavaros
June 1997, American journal of clinical pathology,
C Kouvidou, and K Stefanaki, and Y Dai, and M Tzardi, and K Koutsoubi, and K Darivianaki, and E Karidi, and D Rontogianni, and E Zois, and S Kakolyris, and V Georgoulias, and G Delides, and P Kanavaros
January 1995, Urological research,
C Kouvidou, and K Stefanaki, and Y Dai, and M Tzardi, and K Koutsoubi, and K Darivianaki, and E Karidi, and D Rontogianni, and E Zois, and S Kakolyris, and V Georgoulias, and G Delides, and P Kanavaros
August 1998, Hybridoma,
C Kouvidou, and K Stefanaki, and Y Dai, and M Tzardi, and K Koutsoubi, and K Darivianaki, and E Karidi, and D Rontogianni, and E Zois, and S Kakolyris, and V Georgoulias, and G Delides, and P Kanavaros
June 2003, Journal of experimental & clinical cancer research : CR,
Copied contents to your clipboard!